Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas

Keyphrases

• Recurrent Glioma 100%
• Reoperation 100%
• Recurrent Malignant Glioma 100%
• Interstitial Chemotherapy 100%
• Polymer Drugs 100%
• Well Tolerated 100%
• Polymeric Implants 100%
• Chemotherapy 50%
• Second Dose 50%
• First Dose 50%
• High Dose 50%
• Therapeutic Agents 50%
• Second-line Treatment 50%
• Patient Survival 50%
• Blood Biochemistry 50%
• Biodegradable Polymers 50%
• Systemic Effects 50%
• Difficult-to-treat 50%
• Initial Diagnosis 50%
• Urinalysis 50%
• Phase I Study 50%
• Tumor Debulking 50%
• Tumor Site 50%
• Three-level 50%
• Overall Median Survival 50%
• Sustained Release 50%
• Median Survival Time 50%
• Malignant Glioma 50%
• Wafer 50%
• Mean Survival Time 50%
• Systemic Toxicity 50%
• Polyanhydride 50%
• Carmustine 50%
• Placebo-controlled Clinical Trial 50%
• Adverse Reactions 50%
• Hematology 50%
• Initial Surgery 50%
• Systemic Exposure 50%
• Treatment Dose 50%
• Short Half-life 50%
• Resection Cavity 50%
• Survival Period 50%
• Polymer Release 50%
• Local Exposure 50%
• Intracranial Implants 50%
• BCNU Wafers 50%
• Biodegradable Polymeric Implants 50%

Medicine and Dentistry

• Ganglioglioma 100%
• Carmustine 100%
• Chemotherapy 100%
• Glioblastoma 60%
• Neoplasm 40%
• Survival Time 40%
• Reoperation 40%
• Drug Megadose 20%
• Placebo 20%
• Implant 20%
• Controlled Clinical Trial 20%
• Adverse Drug Reaction 20%
• Hematology 20%
• Urinalysis 20%
• Debulking 20%
• Sustained Drug Release 20%
• Median Survival Time 20%
• Blood Chemistry 20%
• Polyanhydride 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy Regimens 100%
• Carmustine 100%
• Glioblastoma 60%
• Neoplasm 40%
• Survival Time 40%
• Placebo 20%
• Implant 20%
• Controlled Clinical Trial 20%
• Sustained Release 20%
• Median Survival Time 20%
• Adverse Drug Reaction 20%
• Polyanhydride 20%